PLIANT THERAPEUTICS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.6M | $9.7M | $7.6M |
| Operating income | -$156.4M | -$228.4M | -$184.1M | -$127.2M | -$97.5M |
| Operating expenses | $156.4M | $228.4M | $185.7M | $136.9M | $105.1M |
| Cash from operations | -$128.3M | -$155.5M | -$116.4M | -$94.6M | -$75.4M |
| Capital expenditure | $374,000 | $3.8M | $921,000 | $1.8M | $2.0M |
| Free cash flow | -$128.7M | -$159.4M | -$117.3M | -$96.4M | -$77.4M |
| Total assets | $225.2M | $396.9M | $512.2M | $350.6M | $221.2M |
| Total liabilities | $44.0M | $92.9M | $38.6M | $37.3M | $22.2M |
| Total debt | — | $30.0M | $10.0M | $10.0M | $0 |
Shares outstanding 61.9M · Free float 91.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.